FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

(October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading


Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

(October 17, 2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A... Continue Reading


Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

(October 16, 2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients... Continue Reading


Immunotherapy Active Against Triple-Negative Breast Cancer

(October 12, 2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple... Continue Reading


LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

(October 10, 2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition... Continue Reading


FDA approves new treatment for certain advanced or metastatic breast cancers

(October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading


FDA Approves Aliqopa for Relapsed Follicular Lymphoma

(October 4, 2017)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma... Continue Reading


New Standard of Care for Treatment of Resectable Gastric Cancer

(October 3, 2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable... Continue Reading


Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

(September 28, 2017)

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European... Continue Reading


The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

(September 25, 2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors,... Continue Reading


FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

(September 25, 2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab)... Continue Reading


Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

(September 21, 2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC)... Continue Reading


« Previous PageNext Page »